CONTEXT AND OBJECTIVE: Pregnancies complicated by diabetes are associated with increased numbers of maternal and neonatal complications. Hospital costs increase according to the type of care provided. This study aimed to estimate the cost-benefit relationship and social profitability ratio of hospitalization, compared with outpatient care, for pregnant women with diabetes or mild hyperglycemia. METHODS: Thirty pregnant women treated with diet were followed as outpatients, and twenty treated with diet plus insulin were managed through frequent short hospitalizations. Direct costs (personnel, materials and tests) and indirect costs (general expenses) were ascertained from data in the patients' records and the hospital's absorption costing system. The cost-benefit was then calculated. RESULTS: Successful treatment of pregnant women with diabetes avoided expenditure of US$ 1,517.97 and US$ 1,127.43 for patients treated with inpatient and outpatient care, respectively. The cost-benefit of inpatient care was US$ 143,719.16, and outpatient care, US$ 253,267.22, with social profitability of 1.87 and 5.35, respectively. CONCLUSION: Decision-tree analysis confirmed that successful treatment avoided costs at the hospital. Cost-benefit analysis showed that outpatient management was economically more advantageous than hospitalization. The social profitability of both treatments was greater than one, thus demonstrating that both types of care for diabetic pregnant women had positive benefits. 
INTRODUCTION
During their reproductive years, women have higher medical expenditure than men. 1 Such expenditure is mostly related to pregnancy care, childbirth and the ensuing complications.
Pregnancy and childbirth costs include the cost of prenatal care, hospitalizations and neonatal care. These costs increase with the need for hospitalization during pregnancy and length of hospital stays, and according to the mode of delivery.
Adverse gestational outcomes also contribute towards substantially higher costs. 2, 3 Diabetes and mild hyperglycemia during pregnancy increase the costs of prenatal care. Prenatal hospitalization, an approach used in more severe difficult-to-control cases, makes costs even higher. Over the past two decades, improvements in maternal and perinatal outcomes from diabetic pregnancies have been well documented. 4 Moreover, it has also been demonstrated that pregnant women with mild hyperglycemia, i.e. with a normal 100-g glucose tolerance test (GTT) but an abnormal glycemic profile, have perinatal outcomes comparable to those of diabetic women and should, therefore, receive comparable treatment. 5, 6 The principal factor responsible for this is the need for strict glycemic control to maintain blood glucose levels within the normal range throughout pregnancy. 7 To obtain such control, these women are treated with diet and/or insulin therapy, and followed up on an outpatient basis or subjected to frequent short hospitalizations.
The financial and social advantages of outpatient management are intuitively well understood, but a comprehensive comparison of maternal and perinatal outcomes with those of hospitalization is necessary. 8 There are a variety of approaches to cost analysis: absorption costing, procedure cost, activity-based cost, etc. These methods make it possible to produce full or partial assessments. 9 Cost minimization, cost-effectiveness, and cost-benefit analyses are the main types of full analysis. In turn, partial analyses measure the costs attributable to a particular disease and compare costs.
Cost-benefit analysis measures costs and outcomes in monetary units. Because assigning monetary values to pertinent outcomes and human life is difficult, this type of analysis has not often been reported in the literature.
In order to determine the cost-benefit relationship of a treatment protocol, it is necessary to assess its impact on health improvement and the amount of money saved using a specific protocol, or to detail the health benefits achieved at a reasonable cost. [10] [11] [12] Thus, there are some issues that should be taken into consideration. Firstly, treatment expenditure needs to be assessed. Secondly, it has to be borne in mind that some healthcare interventions initially increase the costs with the intent of subsequently providing a monetary saving. Thirdly, some costs are usually underestimated and there are difficulties in assigning values to them, such as the costs relating to pain and the distress of family members, among others. 13 In an era of increasing healthcare costs, understanding the economics of medical care has become yet another requirement for the practice of medicine. 14 Analysis on inpatient insulin treatment for pregnant women with diabetes has shown that this therapeutic strategy is effective.
Despite increasing the cost of gestational diabetes treatment, this can save the additional costs of possible complications. 17 A costconsequence analysis on hospital treatment with insulin among 100 women with gestational diabetes revealed that perinatal morbidity and mortality were reduced. 16 Treatment for diabetes in pregnant women, including different conventional or intensive therapeutic strategies such as outpatient management or hospitalization, increases healthcare expenditure. 2 These high maternal and infant costs incurred during the short period of pregnancy must be analyzed from the perspective of health economics. Therefore, the effectiveness of interventions should be analyzed and demonstrated.
The fundamental principles behind cost-benefit analysis reflect the need to determine an efficient allocation of resources.
Cost-benefit analysis plays a leading role in investigating the usefulness of large-scale projects or interventions. Projects, investments or interventions with positive benefits are candidates for application of such analysis. 13 In Brazil, the cost-benefit relationship of care for pregnant women with diabetes or mild hyperglycemia remains unreported. In these cases, two treatment strategies are used: frequent short hospitalizations or outpatient management. Comparing the costs of these strategies with the maternal and perinatal benefits is necessary.
OBJECTIVES
The purpose of this study was to determine the cost-benefit rela- CIDP-HC-FMB-Unesp adopts the following protocol: pregnant women with pregestational and gestational diabetes or mild hyperglycemia treated with diet therapy are followed in an outpatient setting; women with pregestational and gestational diabetes or mild hyperglycemia treated with diet plus insulin receive in-hospital care.
Direct, indirect and total costs, along with benefits, were prospectively estimated for all pregnant inpatients and outpatients with pregestational and gestational diabetes or mild hyperglycemia, and for their babies. These women started prenatal care in 2007 at CIDP-HC-FMB-Unesp.
The subjects were allocated to one of two groups: inpatientswomen treated with diet plus insulin managed through hospitalization (n = 20); and outpatients -women treated with diet alone on an outpatient basis (n = 30).
Treatment
Pregnant women with pregestational and gestational diabetes or mild hyperglycemia were initially treated with a 2300-calorie diabetic diet individualized to each person's needs and distributed in seven meals. The women who remained euglycemic after receiving this type of treatment were followed up on an outpatient basis until delivery, while those showing high glucose levels during the day despite the diet therapy, received in-hospital care for one day (24 hours) at fortnightly intervals until 28 weeks of gestation, and at weekly intervals from week 28 until delivery.
Exclusion criteria
Women with pregestational and gestational diabetes or mild hyperglycemia who developed clinical problems during gestation or did not give birth at our service were excluded from the study. The costs extracted from the hospital records, as well as those determined using the full costing method, were separated into direct costs (medication, laboratory tests, imaging examinations, supplies, telephone services and personnel) and indirect costs (water supply, sewage services, power supply, general administration and cleaning services) [21] [22] [23] [24] [25] [26] [27] (Table 1 ).
Cost calculation
All costs were expressed in United States dollar values for the year 2009 (US$ 1.00 = R$ 1.97).
Pharmacoeconomic assessment of treatment: building decision trees
Treatment success was assessed on the basis of the following maternal and perinatal parameters: mean glycemia ≤ 120 mg/dl, vaginal delivery, gestational age at birth ≥ 37 weeks, weight adequate for gestational age (AGA), ponderal index < 2.5, 28 infant rooming-in, no maternal mortality and no perinatal mortality.
After the maternal and perinatal criteria for treatment success had been defined, each pregnant woman was classified in accordance with an eight-point scoring system (≥ 6 [equivalent to 75%] = successfully treated; and < 6 = unsuccessfully treated).
For both management methods (outpatient and inpatient), the following were identified: 1) total costs of maternal care (prenatal, childbirth and puerperal) and neonatal care for pregnant women who were successfully or unsuccessfully treated; 2) difference in costs between the treatments. These estimates were used to build a decision tree on the alternatives for managing diabetic pregnant women and their infants.
Benefit calculation
Benefits in monetary units were divided into two subsets: direct benefits and indirect benefits. 11 The direct benefits included the expenditures avoided, according to the maternal and perinatal criteria for successful treatment of diabetes and mild hyperglycemia. The direct benefits in each group were calculated based on the fol- 17.0%) for infants born to diabetic inpatients; and 3.95% (2.9 and 5.0%) for infants born to diabetic outpatients. 8, 21 The indirect benefits were estimated by considering the increase in social productivity that results from low maternal and perinatal mortality. To calculate the indirect benefits, the maternal and perinatal mortality rates were considered to be 2% 21 and 4.5% (2.8-6.2%), [22] [23] [24] [25] [26] [27] respectively. In addition, data from the latest Brazilian census 29 were used to determine the per capita income in the area of Botucatu, state of São Paulo, which was found to be US$ 216.34/month. The average numbers of years of productive life were 60 years for women and 65 years for men. Thus, an average value of 62.5 years was used to determine the number of labor years earned per newborn. The mean age was 31 years among diabetic inpatients, and 32 years among diabetic outpatients.
To calculate the maternal and perinatal direct benefits (DB) and indirect benefits (IB), the following formulae were constructed: The total cost of the benefits was estimated as the sum of all the direct and indirect benefits.
Total benefit cost = Direct benefits (DB 1 + DB 2 + DB 3 + DB 4 + DB 5 + DB 6 + DB 7 + DB 8 + DB 9 ) + indirect benefits (IB 1 + IB 2 )
The investment cost was calculated as the sum of the final average costs of maternal and neonatal care.
Total investment cost = Final weighted average cost of maternal and neonatal care x number of pregnant women investigated
The cost-benefit relationship was determined as the difference between the total benefit cost and the total investment cost. 
Cost-benefit relationship = Total benefit cost (B) minus total investment cost (C)
The social profitability ratio was estimated based on the relationship of the benefit/cost difference divided by cost. 11 A value greater than one indicated that the social value of the benefits exceeded the social value of the costs and that the project/program showed a positive benefit.
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RESULTS

Treatment benefits
The maternal and perinatal outcomes are shown in 
Decision tree and treatment/social profitability cost-benefit assessment
Decision trees (Figures 1 and 2) showed that for 35.0% ( Considering average perinatal mortality rate to be 4.5% (2.8 -6.2%) [23] [24] [25] [26] [27] ; ICU = intensive care unit. 14 To determine whether treating pregnant women with diabetes or mild hyperglycemia provided sufficient benefits to justify its cost, certain steps and criteria were followed. The first step was to define treatment success. Thus, successful treatment was determined based on the recommendations of the St. Vincent Declaration 30 and the criteria of the American Diabetes Association (ADA). 31 The maternal outcomes obtained in this study confirmed that glucose control was more difficult to achieve in diabetic women treated with diet and insulin therapy, who still showed higher glycemic levels despite strict control and treatment. However, the only unfavorable perinatal outcome that correlated with a slightly higher maternal glycemic mean was higher ponderal index. No significant difference was observed among any of the other perinatal parameters.
Treatment success is the main goal of prenatal care for diabetic pregnant women. However, besides the treatment itself, success is also related to patient compliance 32 and the absence of repercussions from hyperglycemia on the placenta. 33 The rate of treatment success involving maternal and perinatal outcomes was much higher when diet therapy alone was used. The final average cost of maternal and neonatal care was higher for dia- In both the inpatient and the outpatient groups that were successfully treated, the number of hospitalizations/visits during pregnancy was reduced; and the length of hospitalization (in days) during pregnancy and childbirth and the infant stay in the neonatal ICU were shorter. However, shorter stays of infants rooming in or receiving nursery care were only observed in the group of diabetic inpatients.
According to Nachum et al., 8 the advantages of outpatient management over hospitalization for pregnant women with diabetes are that it avoids the psychological, mental and social trauma that may result from in-hospital care, prevents disruption of the family unit and enables the patient to continue working.
Home glucose monitoring reflects true ambient glycemic control, and the patient plays an active role in caring for herself. Moreover, these authors reported that all these advantages are associated with a reduction in the costs of diabetes in pregnancy, and
concluded that although these results should be interpreted with caution, outpatient care is as effective as hospitalization for pregnant diabetic women, who benefit from convenience and lower hospital costs.
The analysis on the investment made by the CIDP of HC-FMB-Unesp, regarding different types of care, showed that among pregnant women with diabetes or mild hyperglycemia managed on an outpatient basis, treatment success rates were higher than among those managed by hospitalization. Both the direct and the indirect maternal and neonatal benefits demonstrated that pregnant women with diabetes or mild hyperglycemia treated with diet and insulin therapy were less likely to achieve glycemic control, and therefore benefited less than those managed in an outpatient setting. In consequence, the cost-benefit ratio was lower for diabetic inpatients treated with diet plus insulin. The same occurred regarding the social profitability ratio for the investment.
The costs relating to pregnant inpatients with diabetes or mild hyperglycemia were higher than the costs for such patients treated as outpatients. However, the neonatal outcomes were similar to those observed in the outpatient group, except for the glycemic mean, ponderal index and cesarean delivery rate. These are important findings. Among pregnant women managed through hospitalization, the form of the disease is usually more complex clinically, adequate glycemic control is less likely to be achieved during pregnancy and insulin is required to control maternal glycemia. The decision tree confirmed that treatment success avoided additional costs. The benefits in monetary units were greater than the investment made by the CIDP of HC-FMB-Unesp in different types of care for pregnant women. Outpatient management was economically more advantageous. In addition, it also offered other potential benefits such as preservation of the family unit, avoidance of psychological, mental and social trauma resulting from hospitalization, ability to continue with daily activities and active participation in treatment. Physicians not only need to understand the risks, benefits and economics of treatment, but also must carefully select who to treat, when to treat and for how long to do so, 14 given that as well as being patient advocates, they are also arbiters of societal resources. The results from this study show that the treatment for diabetic pregnant women should be randomized in order to avoid the bias of previously classifying maternal risk and, as a result, to enable management of the most severe cases through frequent short hospitalizations. Using randomization to determine management method so that cost-effectiveness can also be estimated is the next follow-up step to the present study.
CONCLUSIONS
This study made it possible to identify the direct, indirect and total costs and the benefits of prenatal care, delivery care and neonatal care provided by the CIDP of HC-FMB-Unesp.
The maternal and perinatal criteria for treatment success were mean glycemia ≤ 120 mg/dl, vaginal delivery, gestational age at birth ≥ 37 weeks, weight adequate for gestational age (AGA), ponderal index < 2.5, infant rooming-in, no maternal mortality and no perinatal mortality. The decision tree confirmed that treatment success avoided additional costs.
Cost-benefit analysis showed that outpatient management was economically more advantageous than hospitalization. The social profitability of both treatments was greater than one, thus demonstrating that both types of care for diabetic pregnant women had positive benefits.
